Clint Allen

Clint T. Allen, M.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - Clinical Center, Room 7N240C
  • Bethesda, MD 20892
  • 301-827-5620


Dr. Allen’s research centers on immunologic aspects of head and neck cancer and neoplasm development, progression and treatment. Dr. Allen leads a scientific laboratory and clinical research program that focuses on developing novel treatment approaches for human papillomavirus (HPV)-positive and -negative head and neck squamous cell carcinoma as well as recurrent respiratory papillomatosis (RRP). Through close relationships with academic partners in the National Capitol Region community and throughout the country, Dr. Allen maintains a robust referral network for patients interested in prospective immunotherapy clinical trials for newly diagnosed head and neck cancer and RRP.

Board certification:
American Board of Otolaryngology

Areas of Expertise

Head and Neck Squamous Cell Carcinoma

Information for Patients

Learn more about our clinical trials and the highly specialized care teams who lead them.

Clinical Trials


Selected Recent Publications

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-b blockade in HPV-unrelated head and neck cancer

Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CR, Marte JL, Turkbey EB, Mydlarz W, Joshi AS, London NR Jr, Pierce M, Taylor RJ, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT.
J Clin Invest. Jun 21 (online ahead of print): e161400, 2022. [ Journal Article ]

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

Hong Y, Robbins Y, Yang X, Mydlarz WK, Sowers A, Mitchell JB, Gulley JL, Schlom J, Gameiro SR, Sievers C, Allen CT.
JCI Insight. 7(5): e157448, 2022. [ Journal Article ]

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

Sievers C, Robbins Y, Bai K, Yang X, Clavijo PE, Friedman J, Sinkoe A, Norberg SM, Hinrichs C, Van Waes C, Allen CT.
Commun Biol. 4(1): 1416, 2021. [ Journal Article ]

Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells

Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C,
Allen C.
J Immunother Cancer. 9(3): e002128, 2021. [ Journal Article ]

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells

Friedman J, Moore EC, Zolkind P, Robbins Y, Clavijo PE, Sun L, Greene S, Morisada MV, Mydlarz WK, Schmitt N, Hodge JW, Schreiber H, Van Waes C, Uppaluri R, Allen C.
Clin Cancer Res. 26(3): 679-689, 2020. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.